Related Experiment Video

Updated: Jan 13, 2026

Measurement of Antibody Effects on Cellular Function of Isolated Cardiomyocytes
13:42

Measurement of Antibody Effects on Cellular Function of Isolated Cardiomyocytes

Published on: March 8, 2013

12.2K

Successful use of immunoadsorption therapy in advanced dilated cardiomyopathy: A case report

Rendan Zhang1,2, Lvwen Ning1,2, Ying Liu1,2

  • 1Department of Geriatrics, Shenzhen Longhua District Central Hospital, Shenzhen, Guang Dong, P.R. China.

Medicine
|January 10, 2026
PubMed

Insights

Immunoadsorption (IA) may benefit patients with advanced, refractory dilated cardiomyopathy (DCM). This case shows IA improved symptoms and heart function in a treatment-resistant DCM patient.

Area of Science:

  • Cardiology
  • Immunology

Background:

  • Dilated cardiomyopathy (DCM) is a leading cause of heart failure.
  • Some DCM patients do not respond to standard treatments.
  • Immunoadsorption (IA) is an experimental therapy to remove autoantibodies.

Purpose of the Study:

  • To illustrate the potential benefits of IA in advanced, treatment-refractory DCM.
  • To present a case study of IA in a patient with severe DCM.

Main Methods:

  • A patient with advanced DCM and worsening symptoms despite medical therapy was treated.
  • The patient underwent two sessions of immunoadsorption (IA).
  • High-dose intravenous immunoglobulin (IVIG) was administered post-IA.

Main Results:

  • Following IA and IVIG, the patient's symptoms improved.
  • Pro-BNP levels decreased significantly.
  • Left ventricular ejection fraction (LVEF) increased from 22-24% to 29.2%.

Conclusions:

  • Immunoadsorption may be a beneficial adjunctive therapy for refractory DCM.
  • IA shows promise but requires further research in larger studies.
  • This case highlights a potential new treatment avenue for severe heart failure.
Abstract

Keywords:
advanced DCMdilated cardiomyopathyimmunoadsorption therapy

More Related Videos

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

5.3K
Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model14:24

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model

Published on: January 21, 2018

12.1K

Related Concept Videos

Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
455
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
326
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
387
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
439
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
168
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.2K